B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Recent investigations have provided an increasingly complete picture of the genetic
landscape of chronic lymphocytic leukaemia (CLL). These analyses revealed that the CLL …

Myeloid cells can restrain antitumor immunity by metabolic pathways, such as the
degradation of l-arginine, whose concentrations are regulated by the arginase 1 (ARG1) …

Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for
patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides …

TP53 and ataxia telangiectasia mutated (ATM) defects are associated with genomic
instability, clonal evolution, and chemoresistance in chronic lymphocytic leukemia (CLL) …

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in
the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma …

Over the last decade, the active role of the microenvironment in the pathogenesis of B cell
lymphomas has been recognized, delivering signals that favor clonal expansion and drug …

Representing the major cause of morbidity and mortality for chronic lymphocytic leukemia
(CLL) patients, immunosuppression is a common feature of the disease. Effectors of the …

Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed
death-1 is a receptor involved in tumor-mediated immunosuppression through binding of the …

Purpose: Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental
interactions for proliferation and survival that are at least partially mediated through B-cell …